市場調查報告書
商品編碼
1361113
無血清培養基市場規模 - 按類型(CHO 細胞培養、蛋白質表現培養基)、應用(生物製藥生產、幹細胞研究與治療)、最終用戶和全球預測,2023-2032 年Serum-free Media Market Size - By Type (CHO Cell Culture, Protein Expression Media), Application (Biopharmaceutical Production, Stem Cell Research & Therapy), End-user & Global Forecast, 2023-2032 |
由於對先進生物製藥產品的需求不斷增加,預計 2023 年至 2032 年無血清培養基市場規模的年複合成長率將超過 11%。隨著公司不斷開發新療法,他們正在轉向無血清培養系統,以提高生產力、一致性和產品品質。
例如,Thermo Fisher Scientific 的 Gibco 提供了一種由必需營養素和激素配製而成的無血清培養基溶液,無需動物血清即可進行細胞培養。在細胞培養中使用無血清培養基帶來了一系列優勢,包括提高一致性和生產力,以及簡化純化和下游處理。
此外,人們越來越擔心血清衍生成分的安全性和污染的可能性,導致人們轉向無血清培養基,從而消除了這些風險。此外,對客製化培養解決方案的需求以及針對不同研究和生產要求開發化學成分確定的培養基的需求將進一步提振市場。
整個無血清培養基行業根據類型、應用、最終用戶和地區進行分類。
在生物製藥產業不斷擴張的推動下,蛋白質表現介質領域預計 2023 年至 2032 年年複合成長率將達到 11%。隨著研究人員和製造商尋求最佳化重組蛋白、單株抗體和其他生物製劑生產的產量、品質和一致性,專門為蛋白質表現而設計的無血清培養基的需求量很大。這些培養基類型的配方可支持高細胞密度和提高蛋白質生產率,使其在生物製造領域至關重要。
組織工程和再生醫學應用領域預計在2023 年至2032 年期間年複合成長率將達到11.2%。隨著再生療法和組織工程解決方案的發展,針對臨床應用細胞培養和擴增而客製化的無血清培養基的需求不斷增加上升。這些培養基提供支持幹細胞和原代細胞生長和分化所需的精確配方,促進器官移植、傷口癒合和個人化醫療等領域的進步。
亞太地區無血清培養基市場規模預計 2023 年至 2032 年年複合成長率為 11.5%。亞太地區生物技術和製藥業不斷發展,研發投資不斷增加。技術進步迅速,並轉向生物製藥生產。隨著人口的成長、醫療保健投資的增加以及主要參與者的出現,亞太地區的無血清培養基市場將進一步發展。
Serum-free media market size is expected to witness over 11% CAGR from 2023 to 2032 due to the increasing demand for advanced biopharmaceutical products. As companies continue to develop novel therapeutics, they are turning to serum-free culture systems to enhance productivity, consistency, and product quality.
For instance, Thermo Fisher Scientific's Gibco, offers a serum-free media solution formulated with essential nutrients and hormones, allowing for cell culture without the need for animal sera. The utilization of serum-free media in cell culture brings about a range of advantages, including enhanced consistency and productivity, as well as streamlined purification and downstream processing.
Additionally, growing concerns about the safety of serum-derived components and the potential for contamination have led to a shift towards serum-free media, which eliminates these risks. Moreover, the need for customized culture solutions and the development of chemically defined media for diverse research and production requirements will further bolster the market.
The overall serum-free media industry is classified based on type, application, end-user, and region.
The protein expression media segment is expected to register 11% CAGR from 2023 to 2032 driven by the expanding biopharmaceutical sector. Serum-free media designed specifically for protein expression are in high demand as researchers and manufacturers seek to optimize yields, quality, and consistency in the production of recombinant proteins, monoclonal antibodies, and other biologics. These media types are formulated to support high cell densities and increased protein productivity, making them essential in the biomanufacturing landscape.
Tissue engineering & regenerative medicine application segment is predicted to record 11.2% CAGR during 2023 to 2032. As regenerative therapies and tissue engineering solutions gain traction, the demand for serum-free media tailored for the culture and expansion of cells for clinical applications is on the rise. These media offer the precise formulation needed to support the growth and differentiation of stem cells and primary cells, facilitating advancements in areas such as organ transplantation, wound healing, and personalized medicine.
Asia Pacific serum-free media market size is expected to observe 11.5% CAGR from 2023 to 2032. Asia Pacific boasts a growing biotechnology and pharmaceutical sector, with increasing investments in R&D. There are rapid technological advancements and a shift toward biopharmaceutical production. The serum-free media market in Asia Pacific will further bolster with a growing population, rising healthcare investments, and the presence of key players.